Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Amphotericin B · 1 trial · 1 indication
Number of subjects with a clinical response of clinical cure or improvement. Clinical cure was defined as absence of signs or symptoms of infection. Clinical improvement was defined as follows: * OPC or EC: partial resolution defined as greater than or equal to 50% of Baseline signs or symptoms * VVC: reduction of greater than or equal to 50% of clinical severity score from Baseline Severity of each symptom was graded on a scale from zero (absence of symptoms) to 3 (severe symptoms). The sum of all scores for all symptoms was used as the clinical severity score. Higher scores mean worse outcomes.
| Arm | Type | Description |
|---|---|---|
| CAMB (Encochleated Amphotericin B) | EXPERIMENTAL | Encochleated Amphotericin B (200 mg, 400 mg, 800 mg) |
| Name | Type | Description |
|---|---|---|
| Amphotericin B | DRUG | Oral lipid nanocrystal formulation of amphotericin B |
Inclusion Criteria: * Patients must have a clinical diagnosis of at least one of the following: * Persistent oropharyngeal candidiasis (OPC) for greater than or equal to 5 days documented on at least one occasion by potassium hydroxide (KOH) test or fungal stain and confirmed by mycological culture...
Amphotericin B is being studied for the treatment of Chronic Mucocutaneous Candidiasis, a persistent fungal infection. It is an investigational small molecule in Phase 2 clinical development. The drug is being evaluated for its ability to address this condition, though it is not yet approved for this use.
Amphotericin B is being developed by Matinas Biopharma Holdings, Inc., a biopharmaceutical company traded on the NYSE American under the ticker symbol MTNB. The company is conducting clinical research on this drug for the treatment of Chronic Mucocutaneous Candidiasis.
Amphotericin B is in Phase 2 clinical development for Chronic Mucocutaneous Candidiasis. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 2 study has been completed, and the drug remains under evaluation for this indication.
Amphotericin B has one completed Phase 2 clinical trial registered as NCT02629419, titled "CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis." The study enrolled 4 participants in the United States and was an uncontrolled, non-randomized trial. No active trials are currently listed for this drug.
Amphotericin B is also known as MAT2203, as indicated by the clinical trial title. The Phase 2 study NCT02629419 refers to the drug as CAMB/MAT2203, confirming that MAT2203 is an alternative name for Amphotericin B in this development program.